Today we are delighted to announce the further expansion of our collaboration with Lilly. Lilly is a leader in innovative RNA science, making them a great partner for our Axiomer technology.
ProQR & Lilly Partnership Expansion Today marks an expansion of the ProQR and Lilly partnership
In September 2021 ProQR announced a global licensing and research collaboration with Lilly. The partnership focuses on developing potential medicines using our Axiomer RNA editing platform technology. Strategic collaborations like this can help to drive the advancement of an early-stage technology, like Axiomer, closer to the clinic.
Since the beginning, ProQR has been focused on RNA technologies to develop medicines for people and families with high unmet medical need. In August of this year, we focused our strategy exclusively on furthering the development of our Axiomer RNA editing platform technology, which allows selective editing of individual bases in the RNA. The collaboration, originally announced in September 2021, applied ProQR’s proprietary Axiomer® RNA editing platform to target disorders of the liver and nervous system. Through the course of work to date, advances in the platform have significantly increased editing efficiency and refined biodistribution in both the liver and nervous system, opening up new potential applications to not only correct known mutations, but also introduce protective variants in specific transcripts.
Through this expanded collaboration, Lilly and ProQR will explore further applications of the Axiomer platform to unlock new innovative treatments for people living with diseases with high unmet medical need.
Discovering and developing the medicines of tomorrow takes time, sustained innovation and most importantly, collaboration.
“Discovering and developing the medicines of tomorrow takes time, sustained innovation and most importantly, collaboration. We have been impressed with the progress to date with our partners at ProQR and have conviction that RNA editing can be an important alternative to other more permanent therapies,” says Andrew C. Adams, Ph.D., Lilly senior vice president of genetic medicine and co-director of the Institute for Genetic Medicine
Since 2014, we have advanced our science, built out an extensive intellectual property portfolio with more than 10 patent families, generated scientific expertise and know-how around this game-changing platform. As with our mission when we started in 2012, all this work is aimed at developing medicines for communities with high unmet medical needs.
We look forward to making an impact on the lives of patients together with Lilly.
“Our original collaboration with Lilly, which leverages our Axiomer RNA editing technology platform, continues to progress well and we are pleased to be expanding our partnership to include additional targets, along with an option for Lilly to opt in for more. Lilly is a leader in RNA therapeutics, and our expanded partnership is another validation of our leadership in ADAR-mediated RNA editing, our robust IP estate, and the potential of our broadly applicable Axiomer platform technology. We look forward to making an impact on the lives of patients together with Lilly,” says Daniel A. de Boer, founder, and CEO of ProQR.
The expansion of our partnership with Lilly today is a further validator of our leadership in ADAR-mediated RNA editing, our robust intellectual property, and the potential of our broadly applicable Axiomer platform technology.
For more information, please read our latest press release.
